Lotrafiban

洛曲非班

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameLotrafiban
Drug Alias NameSB-214857SB-214134SB-214857A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionIntegrin alpha-IIb/beta-3 antagonists
TargetsIntegrin alpha-IIb/beta-3
Therapy Area/IndicationsThrombosisCerebrovascular Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsThrombosisCerebrovascular Disorders

Other Information

ATC CodeN/A
Related LinksKEGG